Dianthus Therapeutics Future Growth
Future criteria checks 2/6
Dianthus Therapeutics's earnings are forecast to decline at 22.1% per annum while its annual revenue is expected to grow at 68.8% per year. EPS is expected to decline by 3.2% per annum.
Key information
-22.1%
Earnings growth rate
-3.2%
EPS growth rate
Biotechs earnings growth | 24.8% |
Revenue growth rate | 68.8% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 10 May 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 3 | -123 | -98 | N/A | 5 |
12/31/2025 | 2 | -90 | -86 | N/A | 6 |
12/31/2024 | 2 | -67 | -78 | N/A | 5 |
3/31/2024 | 3 | -50 | N/A | N/A | N/A |
12/31/2023 | 3 | -44 | -37 | -37 | N/A |
9/30/2023 | 4 | -43 | -34 | -34 | N/A |
6/30/2023 | 4 | -36 | -32 | -32 | N/A |
3/31/2023 | 6 | -31 | -34 | -34 | N/A |
12/31/2022 | 6 | -28 | -29 | -29 | N/A |
12/31/2021 | 1 | -13 | -10 | -10 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DNTH is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: DNTH is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: DNTH is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: DNTH's revenue (68.8% per year) is forecast to grow faster than the US market (8.3% per year).
High Growth Revenue: DNTH's revenue (68.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if DNTH's Return on Equity is forecast to be high in 3 years time